Zoetis Inc. (ZTS)

Market Closed

16 Oct, 08:00 PM

NYSE

79. 38

+0.96

+1.2242%

32.78B Market Cap

29.76 P/E Ratio

2.12% Div Yield

5.57M Volume

5.79 Eps

$ 78.42

Previous Close

Investors:

TJD

+386

Analysts:

Add Transaction

Day Range

78.29 80.59

Year Range

68.77 148.3

Want to track ZTS and more in your Portfolio? 🎯

Get Started For Free

Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of Zoetis (ZTS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 8 months ago

Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 8 months ago

Here's Why Zoetis (ZTS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 8 months ago

Here's Why Zoetis (ZTS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 8 months ago

Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 8 months ago

Zoetis: Undervalued And Oversold

Zoetis, the global animal health leader, is deeply undervalued at a 19x forward P/E versus its 10-year average of 31.8x. ZTS is positioned to benefit from the secular trend of pet humanization, with 66% of revenue from companion animal products. Consensus expects 8.9% annual EPS growth and 9%-10% dividend growth, supporting a fair value estimate of $170 per share.

Seekingalpha | 8 months ago

Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 8 months ago

Zoetis: Cheap Valuation And Attractive Product Launch Pipeline

I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial first-mover advantages. The CKD monoclonal antibody for canine renal disease, launching in 2027, could unlock a $3–4 billion market with recurring revenue potential.

Seekingalpha | 9 months ago